April 8, 2010

To whom it may concern:

Company Name : TOHO HOLDINGS CO., LTD. Representative : Norio Hamada / President and CEO (Securities Code: 8129 / Tokyo Stock Exchange) Contact : Mamoru Ishii, Corporate Officer and General Manager of Corporate Planning Office (TEL: 03-5259-9500)

Notice Regarding the Business Reorganization of ASUCOME CO., LTD., a Wholly Owned Sub-subsidiary of TOHO HOLDINGS CO., LTD.

TOHO HOLDINGS CO., LTD. is pleased to announce that at the meeting of its Board of Directors held today (April 8, 2010), it was resolved to reorganize businesses of ASUCOME CO., LTD., a wholly owned sub-subsidiary of the Company. The details are as follows:

1. Purpose of Business Reorganization

The Kyoso Mirai Group, with TOHO HOLDINGS as its core company, is a corporate group engaged in the distribution of pharmaceutical and other medical products. It has been working toward maximizing its group synergy through active use of managerial resources of all member companies under the group slogan, "Total Commitment to Good Health."

The Group has adopted a business management and control system under which the pharmaceutical wholesaling and the dispensing pharmacy businesses are centered on TOHO PHARMACEUTICAL CO., LTD., a wholly owned subsidiary of TOHO HOLDINGS (hereinafter "Toho Pharmaceutical"), and PharmaCluster Co., Ltd., another wholly owned subsidiary of the Company (hereinafter "PharmaCluster"), respectively. The Company today decided to reorganize businesses of ASUCOME CO., LTD. (hereinafter "Asucome"), which became a wholly owned subsidiary of Toho Pharmaceutical on February 1, 2010, with the aim of optimizing group-wide managerial resources and maximizing its corporate value, and in order to promptly respond to the drastically changing business environment.

2. Outline of Business Reorganization

- (1) The dispensing pharmacy business of Asucome is scheduled to be spun off to form a subsidiary of PharmaCluster on July 1, 2010.
- (2) The pharmaceutical wholesaling business of Asucome in Ibaraki prefecture is scheduled to be integrated into Yamaguchi Toho, a wholly owned subsidiary of Toho Pharmaceutical, on July 1, 2010.
- (3) Toho Pharmaceutical and Asucome are scheduled to be merged on October 1, 2010.

3. Methods, Schedule and Details of Business Reorganization

Specific details about the method and the schedule of the business reorganization of Asucome will be announced immediately after they have been finalized.

4. Impact on Earnings

Since member companies of the Group, i.e. wholly owned subsidiaries and wholly owned sub-subsidiaries of TOHO HOLDINGS, alone are subject to the business reorganization, its impact on the Company's consolidated earnings for the fiscal year ending March 2011 will be minimal.